Similarly to MMR deficiency detection by IHC, a validated optimized laboratory protocol together with a correct pathological interpretation of p53 immunohistochemical staining are fundamental to achieve high diagnostic accuracy in predicting the presence of TP53 mutation, in this way selecting candidate patients for targeted therapy with PARP inhibitors. This evidence concerns the gene PARP1 and mismatch repair cancer syndrome 1.